Acne Related to Dietary Supplements
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pediatric and Adolescent Dermatology
Pediatric and adolescent dermatology Management and referral guidelines ICD-10 guide • Acne: L70.0 acne vulgaris; L70.1 acne conglobata; • Molluscum contagiosum: B08.1 L70.4 infantile acne; L70.5 acne excoriae; L70.8 • Nevi (moles): Start with D22 and rest depends other acne; or L70.9 acne unspecified on site • Alopecia areata: L63 alopecia; L63.0 alopecia • Onychomycosis (nail fungus): B35.1 (capitis) totalis; L63.1 alopecia universalis; L63.8 other alopecia areata; or L63.9 alopecia areata • Psoriasis: L40.0 plaque; L40.1 generalized unspecified pustular psoriasis; L40.3 palmoplantar pustulosis; L40.4 guttate; L40.54 psoriatic juvenile • Atopic dermatitis (eczema): L20.82 flexural; arthropathy; L40.8 other psoriasis; or L40.9 L20.83 infantile; L20.89 other atopic dermatitis; or psoriasis unspecified L20.9 atopic dermatitis unspecified • Scabies: B86 • Hemangioma of infancy: D18 hemangioma and lymphangioma any site; D18.0 hemangioma; • Seborrheic dermatitis: L21.0 capitis; L21.1 infantile; D18.00 hemangioma unspecified site; D18.01 L21.8 other seborrheic dermatitis; or L21.9 hemangioma of skin and subcutaneous tissue; seborrheic dermatitis unspecified D18.02 hemangioma of intracranial structures; • Tinea capitis: B35.0 D18.03 hemangioma of intraabdominal structures; or D18.09 hemangioma of other sites • Tinea versicolor: B36.0 • Hyperhidrosis: R61 generalized hyperhidrosis; • Vitiligo: L80 L74.5 focal hyperhidrosis; L74.51 primary focal • Warts: B07.0 verruca plantaris; B07.8 verruca hyperhidrosis, rest depends on site; L74.52 vulgaris (common warts); B07.9 viral wart secondary focal hyperhidrosis unspecified; or A63.0 anogenital warts • Keratosis pilaris: L85.8 other specified epidermal thickening 1 Acne Treatment basics • Tretinoin 0.025% or 0.05% cream • Education: Medications often take weeks to work AND and the patient’s skin may get “worse” (dry and red) • Clindamycin-benzoyl peroxide 1%-5% gel in the before it gets better. -
(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities. -
Cutaneous Adverse Effects of Biologic Medications
REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions -
General Dermatology an Atlas of Diagnosis and Management 2007
An Atlas of Diagnosis and Management GENERAL DERMATOLOGY John SC English, FRCP Department of Dermatology Queen's Medical Centre Nottingham University Hospitals NHS Trust Nottingham, UK CLINICAL PUBLISHING OXFORD Clinical Publishing An imprint of Atlas Medical Publishing Ltd Oxford Centre for Innovation Mill Street, Oxford OX2 0JX, UK tel: +44 1865 811116 fax: +44 1865 251550 email: [email protected] web: www.clinicalpublishing.co.uk Distributed in USA and Canada by: Clinical Publishing 30 Amberwood Parkway Ashland OH 44805 USA tel: 800-247-6553 (toll free within US and Canada) fax: 419-281-6883 email: [email protected] Distributed in UK and Rest of World by: Marston Book Services Ltd PO Box 269 Abingdon Oxon OX14 4YN UK tel: +44 1235 465500 fax: +44 1235 465555 email: [email protected] © Atlas Medical Publishing Ltd 2007 First published 2007 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Clinical Publishing or Atlas Medical Publishing Ltd. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention. A catalogue record of this book is available from the British Library ISBN-13 978 1 904392 76 7 Electronic ISBN 978 1 84692 568 9 The publisher makes no representation, express or implied, that the dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. -
Jemds.Com Original Research Article
Jemds.com Original Research Article DERMATOLOGICAL ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS: EXPERIENCE FROM A TERTIARY CENTRE Parvaiz Anwar Rather1, M. Hussain Mir2, Sandeep Kaul3, Vikas Roshan4, Jilu Mathews5, Bandu Sharma6 1Lecturer, Department of Dermatology, GMC, Jammu, Jammu & Kashmir, India. 2Consultant, Department of Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 3Consultant, Department of Surgical Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 4Consultant, Department of Radiation Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 5Senior Nursing In Charge, Department of Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. 6Senior Nursing In Charge, Department of Oncology, Narayana Superspeciality Hospital, Katra, Jammu, Jammu & Kashmir, India. ABSTRACT BACKGROUND Chemotherapeutic agents, both conventional and new targeted therapy, are known to cause diverse side effects related to skin, hair, mucous membranes and nails, collectively called `dermatological adverse effects`. But such association in literature is mostly confined to case reports/case series and small number of published papers. The aim of this study is to look for dermatological adverse effects and the most common culprit agents, with the objective that the oncologist and dermatologist team remain vigilant and adopt rational management protocol in their management to circumvent the morbidity and long-term toxicity as it involves the cosmetic appearance of long-term cancer survivor. MATERIALS AND METHODS This prospective hospital-based descriptive study was conducted jointly by the dermatologist and oncology team over a period of more than one year in a specialised tertiary centre on oncology patients, who developed dermatological side effects after initiation of anti-cancer drugs. RESULTS Out of 125 patients studied, dermatological adverse effects of varying duration were noticed in 27 patients (21.6%), with overall 45 side effects manifestation. -
Drug-Induced Acneiform Eruptions
View metadata, citation and similar papers at core.ac.uk brought to you by CORE We are IntechOpen, provided by IntechOpen the world’s leading publisher of Open Access books Built by scientists, for scientists 4,800 122,000 135M Open access books available International authors and editors Downloads Our authors are among the 154 TOP 1% 12.2% Countries delivered to most cited scientists Contributors from top 500 universities Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI) Interested in publishing with us? Contact [email protected] Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com Chapter 5 Drug-Induced Acneiform Eruptions Emin Özlü and Ayşe Serap Karadağ EminAdditional Özlü information and Ayşe is available Serap at Karadağ the end of the chapter Additional information is available at the end of the chapter http://dx.doi.org/10.5772/65634 Abstract Acne vulgaris is a chronic skin disease that develops as a result of inflammation of the pilosebaceous unit and its clinical course is accompanied by comedones, papules, pus- tules, and nodules. A different group of disease, which is clinically similar to acne vul- garis but with a different etiopathogenesis, is called “acneiform eruptions.” In clinical practice, acneiform eruptions are generally the answer of the question “What is it if it is not an acne?” Although there are many subgroups of acneiform eruptions, drugs are common cause of acneiform eruptions, and this clinical picture is called “drug-induced acneiform eruptions.” There are many drugs related to drug-induced acneiform erup- tions. -
Practical Dermatology Methodical Recommendations
Vitebsk State Medical University Practical Dermatology Methodical recommendations Adaskevich UP, Valles - Kazlouskaya VV, Katina MA VSMU Publishing 2006 616.5 удк-б-1^«адл»-2о -6Sl«Sr83p3»+4£*łp30 А28 Reviewers: professor Myadeletz OD, head of the department of histology, cytology and embryology in VSMU: professor Upatov Gl, head of the department of internal diseases in VSMU Adaskevich IIP, Valles-Kazlouskaya VV, Katina МЛ. A28 Practical dermatology: methodical recommendations / Adaskevich UP, Valles-Kazlouskaya VV, Katina MA. - Vitebsk: VSMU, 2006,- 135 p. Methodical recommendations “Practical dermatology” were designed for the international students and based on the typical program in dermatology. Recommendations include tests, clinical tasks and practical skills in dermatology that arc used as during practical classes as at the examination. УДК 616.5:37.022.=20 ББК 55.83p30+55.81 p30 C Adaskev ich UP, Valles-Ka/.louskaya VV, Katina MA. 2006 OVitebsk State Medical University. 2006 Content 1. Practical skills.......................................................................................................5 > 1.1. Observation of the patient's skin (scheme of the case history).........................5 1.2. The determination of skin moislness, greasiness, dryness and turgor.......... 12 1.3. Dermographism determination.........................................................................12 1.4. A method of the arrangement of dropping and compressive allergic skin tests and their interpretation........................................................................................................ -
An Update on the Treatment of Rosacea
VOLUME 41 : NUMBER 1 : FEBRUARY 2018 ARTICLE An update on the treatment of rosacea Alexis Lara Rivero Clinical research fellow SUMMARY St George Specialist Centre Sydney Rosacea is a common inflammatory skin disorder that can seriously impair quality of life. Margot Whitfeld Treatment starts with general measures which include gentle skin cleansing, photoprotection and Visiting dermatologist avoidance of exacerbating factors such as changes in temperature, ultraviolet light, stress, alcohol St Vincent’s Hospital Sydney and some foods. Senior lecturer For patients with the erythematotelangiectatic form, specific topical treatments include UNSW Sydney metronidazole, azelaic acid, and brimonidine as monotherapy or in combination. Laser therapies may also be beneficial. Keywords For the papulopustular form, consider a combination of topical therapies and oral antibiotics. flushing, rosacea Antibiotics are primarily used for their anti-inflammatory effects. Aust Prescr 2018;41:20-4 For severe or refractory forms, referral to a dermatologist should be considered. Additional https://doi.org/10.18773/ treatment options may include oral isotretinoin, laser therapies or surgery. austprescr.2018.004 Patients should be checked after the first 6–8 weeks of treatment to assess effectiveness and potential adverse effects. Introduction • papules Rosacea is a common chronic relapsing inflammatory • pustules skin condition which mostly affects the central face, • telangiectases. 1 with women being more affected than men. The In addition, at least one of the secondary features pathophysiology is not completely understood, but of burning or stinging, a dry appearance, plaque dysregulation of the immune system, as well as formation, oedema, central facial location, ocular changes in the nervous and the vascular system have manifestations and phymatous changes are been identified. -
A Very Rare Case of Dissecting Cellulitis of the Scalp in an Indonesian Man
A Very Rare Case of Dissecting Cellulitis of the Scalp in an Indonesian Man Rizky Lendl Prayogo1, Lusiana1, Sri Linuwih Menaldi1, Sondang P. Sirait1, Eliza Miranda1 1Department of Dermatology and Venereology Faculty of Medicine Universitas Indonesia / Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia Keywords: dissecting cellulitis of the scalp, dissecting folliculitis, follicular occlusion tetrad, diagnosis, isotretinoin Abstract: Dissecting cellulitis of the scalp (DCS), also known as dissecting folliculitis, perifolliculitis capitis abscedens et suffodiens (PCAS), or Hoffman’s disease, is a primary neutrophilic cicatricial alopecia without clear etiology. Along with hidradenitis suppurativa, acne conglobata, and pilonidal cyst, they were recognized as ‘follicular occlusion tetrad’. A 43-year-old Indonesian man presented to our department with four years history of persistent, slightly painful subcutaneous nodules, abscesses, and sinuses that discharged purulent exudate on vertex and occipital scalp. There was also associated patchy alopecia. He had severe acne during his adolescence to early adulthood. Trichoscopic evaluation showed yellowish and whitish area lacking of follicular openings. Histopathological examination showed follicular occlusion, dilatation, and rupture with mixed inflammatory infiltrates, mainly neutrophils. The diagnosis of DCS was confirmed by clinical, trichoscopic, and histopathological examinations. Isotretinoin 20 mg daily was given to normalize the follicular keratinization. Considering its very rare occurrence in an Indonesia man, this case was reported to emphasize the diagnosis of DCS. 1 INTRODUCTION should be considered (Otberg & Shapiro, 2012; Scheinfeld, 2014). Considering its low prevalence in DCS, also known as dissecting folliculitis, PCAS, Indonesia, we are intrigued to report a case or Hoffmann’s disease, is a very rare primary emphasizing the diagnosis of DCS. -
Acne Conglobata Associated with Hidradenitis Suppurativa, Disorders of Follicular Occlusion (Case Report)
30 ACTA MEDICA MARTINIANA 2015 15/2 DOI: 10.1515/acm-2015-0009 ACNE CONGLOBATA ASSOCIATED WITH HIDRADENITIS SUPPURATIVA, DISORDERS OF FOLLICULAR OCCLUSION (CASE REPORT) Pecova K, jr. Department of of Dermatovenerology, Comenius University, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Slovakia Abstract The author is presenting the case of a 23-year-old female patient with a severe form of acne conglobata, with the first symptoms of the disease occurring as far back as the prepubertal age. In the past year the disease has com- bined with hidradenitis suppurativa (to be referred to henceforth as “HS”), Hurley stage I, in the axillae and both sides of the inguinal region, with a family history of acne conglobata (both her mother and brother were affected). Further examinations ruled out inflammatory bowel disease because of a lack of further associated symptoms, except for sideropenic anaemia (lesser form) and lower serum values of vitamin D. Up until now the disease has been resistant to treatment, including the long-term treatment of methylprednisolone in combination with isotretinoid as well as dapsone and antibiotics. Key words: acne conglobata, hidradenitis suppurativa, treatment INTRODUCTION Hidradenitis suppurativa (HS) may occur in combination with a severe form of acne (acne conglobata), dissecting cellulitis of the scalp and pilonidal sinus (pilonidal cysts) [1]. We present a case of the simultaneous occurrence of the symptoms of severe acne con- globata and HS. Case report A 23-year old female patient (175 cm tall, 60 kg weight, BMI -19.2), mother of two chil- dren, currently on maternal leave, with smoking being ruled out, and with her mother and brother having been treated for severe symptoms of acne conglobata. -
Steroid-Induced Rosacealike Dermatitis: Case Report and Review of the Literature
CONTINUING MEDICAL EDUCATION Steroid-Induced Rosacealike Dermatitis: Case Report and Review of the Literature Amy Y-Y Chen, MD; Matthew J. Zirwas, MD RELEASE DATE: April 2009 TERMINATION DATE: April 2010 The estimated time to complete this activity is 1 hour. GOAL To understand steroid-induced rosacealike dermatitis (SIRD) to better manage patients with the condition LEARNING OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Explain the clinical features of SIRD, including the 3 subtypes. 2. Evaluate the multifactorial pathogenesis of SIRD. 3. Recognize the importance of a detailed patient history and physical examination to diagnose SIRD. INTENDED AUDIENCE This CME activity is designed for dermatologists and generalists. CME Test and Instructions on page 195. This article has been peer reviewed and approved Einstein College of Medicine is accredited by by Michael Fisher, MD, Professor of Medicine, the ACCME to provide continuing medical edu- Albert Einstein College of Medicine. Review date: cation for physicians. March 2009. Albert Einstein College of Medicine designates This activity has been planned and imple- this educational activity for a maximum of 1 AMA mented in accordance with the Essential Areas PRA Category 1 Credit TM. Physicians should only and Policies of the Accreditation Council for claim credit commensurate with the extent of their Continuing Medical Education through the participation in the activity. joint sponsorship of Albert Einstein College of This activity has been planned and produced in Medicine and Quadrant HealthCom, Inc. Albert accordance with ACCME Essentials. Dr. Chen owns stock in Merck & Co, Inc. Dr. Zirwas is a consultant for Coria Laboratories, Ltd, and is on the speakers bureau for Astellas Pharma, Inc, and Coria Laboratories, Ltd. -
Common Dermatological Conditions
Produced: 13/01/2017 Common Dermatological Conditions Dr Alvin Chong Senior Lecturer Dr Catherine Scarff Senior Lecturer Dr Laura Scardamaglia Clinical Senior Lecturer Produced: 13/01/2017 Learning objectives: Describe the common features of • Eczema variants and psoriasis • Acne and rosacea • Scabies • Understand the principles of investigation and treatment for common dermatological problems Produced: 13/01/2017 Case: A 22 year old student presents with 3 months of worsening rash. Not responding to 1% hydrocortisone cream. Produced: 13/01/2017 Erythematous, ill defined, scaly, patches in flexures Produced: 13/01/2017 Diagnosis: Atopic eczema Produced: 13/01/2017 Atopic Eczema • Genetic predisposition Clinical features (Family history) • Itchy ++ • Atopic triad • Erythematous - Asthma • Diffuse - Hayfever • Flexural- thinnest skin - Eczema • Worse in winter (dry) • Worse in summer (heat) Produced: 13/01/2017 Atopic Eczema Model Genetic Predisposition Environmental -Filaggrin mutation- Triggers Leads to reduced barrier •Irritants (soaps etc) function •Allergy •Heat •Infection (Staph.) •“Itch-scratch cycle” •Stress and anxiety 1. Palmer et al Nat. Genet. 38,441-6 Eczema Produced: 13/01/2017 Atopic eczema in an infant Produced: 13/01/2017 3 year old girl, eczema since infancy Produced: 13/01/2017 35 year old man with longstanding eczema mainly of the flexures. Produced: 13/01/2017 Lichenification: The result of chronic rubbing and scratching Produced: 13/01/2017 Eczema Variants Produced: 13/01/2017 Discoid Eczema • Eczema in annular disc